# A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT07150988** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** HSK44459 dose level 1
- **DRUG:** HSK44459 dose level 2
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT07150988
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-26
- **Primary completion:** 2026-11-06
- **Final completion:** 2026-11-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07150988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07150988, "A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07150988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*